Tdspharm Co., Ltd. (KOSDAQ:464280)
6,010.00
+160.00 (2.74%)
Aug 12, 2026, 3:30 PM KST
Tdspharm Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 30,411 | 27,621 | 27,519 | 30,049 | 25,588 | 19,820 |
Revenue Growth | 19.57% | 0.37% | -8.42% | 17.43% | 29.11% | 9.97% |
Gross Profit Gross Profit Growth | 8,587 | 7,489 | 7,701 | 7,910 | 6,134 | 3,956 |
Operating Income Operating Income Growth | 4,920 | 3,765 | 3,730 | 5,016 | 3,781 | 2,314 |
Net Income Net Income Growth | 5,055 | 4,275 | 3,718 | 4,688 | 3,456 | 2,063 |
Earnings Per Share EPS Growth | 956.71 | 808.27 | 803.00 | 1101.00 | 811.00 | 22325.01 |
EPS Growth | 42.92% | 0.66% | -27.07% | 35.76% | -96.37% | 65.21% |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cataplasma Cataplasma Growth | 20,716 | - | - | - |
Plasta Plasta Growth | 4,453 | - | - | - |
Excluding Solid Content Excluding Solid Content Growth | 2,349 | - | - | - |
Cataplasma - All-in-One Cataplasma - All-in-One Growth | - | 17,070 | 13,548 | 9,021 |
Cataplasma - Detachable Cataplasma - Detachable Growth | - | 5,012 | 6,427 | 5,651 |
Prescription Drugs Prescription Drugs Growth | - | 2,979 | 2,162 | 2,289 |
Plasta - Menstruum Plasta - Menstruum Growth | - | 2,726 | 1,435 | 1,615 |
Plasta - Hot Melt Plasta - Hot Melt Growth | - | 2,263 | 1,401 | 942 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 28,295 | 20,213 | 30,704 | 15,136 | 9,937 | 8,122 |
Total Debt Total Debt Growth | 13,902 | 7,712 | 6,926 | 7,145 | 6,951 | 7,140 |
Net Cash (Debt) Net Cash Growth | 14,394 | 12,501 | 23,778 | 7,991 | 2,986 | 982.27 |
Net Cash Growth | -34.12% | -47.43% | 197.58% | 167.60% | 203.99% | 249.25% |
Net Cash Per Share Net Cash Per Share Growth | 2724.37 | 2363.85 | 5135.78 | 1876.65 | 700.79 | 10630.51 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4,945 | 3,780 | 3,929 | 3,294 | 2,942 | 3,680 |
Capital Expenditures CapEx Growth | -13,243 | -12,884 | -715.7 | -213.82 | -625.42 | -200.89 |
Free Cash Flow Free Cash Flow Growth | -8,298 | -9,104 | 3,213 | 3,080 | 2,317 | 3,479 |
Free Cash Flow Growth | - | - | 4.34% | 32.92% | -33.40% | 75.45% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 28.24% | 27.12% | 27.98% | 26.32% | 23.97% | 19.96% |
Operating Margin | 16.18% | 13.63% | 13.55% | 16.69% | 14.77% | 11.68% |
Pretax Margin | 19.77% | 18.00% | 15.30% | 18.27% | 15.03% | 12.20% |
Profit Margin | 16.62% | 15.48% | 13.51% | 15.60% | 13.51% | 10.41% |
FCF Margin | -27.29% | -32.96% | 11.68% | 10.25% | 9.05% | 17.55% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 6.28 | 12.74 | 19.69 | - | - | - |
P/FCF Ratio | - | - | 22.79 | - | - | - |
PS Ratio | 1.09 | 1.97 | 2.66 | - | - | - |